Answers are grounded in this paper and cite their sources.
More than 95% of prostate cancers are adenocarcinoma, and neuroendocrine carcinomas (NECs) are very rare, representing less than 1% of prostate cancers. Among NECs of the prostate including small cell carcinoma (SmCC), carcinoids, and large cell neuroendocrine carcinoma (LCNEC), LCNEC is extremely rare. Only 15 cases have been reported to date and their prognoses were very poor. Here, we report a patient with de novo LCNEC of the prostate that was successfully treated with radical surgery and adjuvant androgen deprivation therapy (ADT).
No takes yet. Share an insight, caveat, or question.
Miyakawa et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: